Publications by authors named "Timothy Cannon"

Claim this Profile
F
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program.
Salvador Alonso, Kanwal Raghav, Van K Morris, Kristin Alfaro-Munoz, Tanios Bekaii-Saab, Timothy L Cannon

Cancer Cell· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib in Patients With Solid Tumors With Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Oxana V Crysler, Timothy L Cannon

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities.
Sanja Karovic, Erik Dvergsten, Chiara Pierattini, Ana Barac, Lauren Fay, Timothy L Cannon

Cancer Res Commun· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
Changsong Qi, Lin Shen, Thierry Andre, Hyun Cheol Chung, Timothy L Cannon

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boards.
Allison L Hunt, Jamie Randall, Mahesh M Mansukhani, Kara Nyberg, Aratara Nutcharoen, Timothy L Cannon

NPJ Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRE25-033: A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib.
Nina Neill, Timothy Cannon, Raymond Wadlow

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Timothy L Cannon

JCO Precis Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Hirra A Chaudhary, Timothy L Cannon, Arthur Winer

Drugs R D· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer.
Laura E Johnston, Jamie Randall, Safae Chouraichi, Mary Luu, Allison L Hunt, Timothy L Cannon

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.
Jamie Randall, Allison L Hunt, Aratara Nutcharoen, Laura Johnston, Safae Chouraichi, Timothy L Cannon

Clin Proteomics· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Herbert L Duvivier, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn, Timothy L Cannon

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Rodolfo Gutierrez, Timothy L Cannon

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
Allison L Hunt, Aratara Nutcharoen, Jamie Randall, Alyssa Papazian, John Deeken, Timothy L Cannon

Oncologist· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
Megan P Hitchins, Rocio Alvarez, Lisa Zhou, Francesca Aguirre, Estela Dámaso, Timothy Cannon

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, Pam K Mangat, Reza Nazemzadeh, Timothy L Cannon

JCO Precis Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Timothy Lewis Cannon, Jamie N Randall, Ethan S Sokol, Sonja M Alexander, Raymond C Wadlow

Cancer Treat Res Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.
Khaled W Kabbara, Timothy Cannon, Arthur Winer, Raymond C Wadlow

Oncology (Williston Park)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient attendance at molecular tumor board: A new means of shared decision making?
Timothy Lewis Cannon, Laura Knopp, Hongkun Wang, Tiffani DeMarco, John Milburn Jessup

Curr Probl Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Case Series Analysis of Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
Andrew Hendifar, Edik M Blais, Brian Wolpin, Vivek Subbiah, Eric Collisson, Timothy Cannon

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote Home Monitoring of Patients With Cancer During the COVID Pandemic: A Pilot Study.
Mary Steimer, Jessica Leabo, Hongkun Wang, David Heyer, Nancy Addison, Timothy L Cannon

JCO Oncol Pract· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra, Timothy L Cannon

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
Nathan A Pennell, Melissa Dillmon, Laura A Levit, E Allyn Moushey, Ajjai S Alva, Timothy L Cannon

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Elie G Dib, Timothy L Cannon

JCO Precis Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis